Search. Learn. Save

Platform for Pharmaceutical Products for Healthcare Professionals
Search By
☰ Generic Formulas

Generic Formulas X

Caspofungin

Caspofungin: A Powerful Echinocandin in the Antifungal Arsenal

Introduction

Fungal infections, particularly in immunocompromised individuals, have become a significant challenge in modern clinical practice. Among the diverse arsenal of antifungal agents, Caspofungin has emerged as a cornerstone in treating invasive fungal infections. As the first approved member of the echinocandin class, Caspofungin offers a novel mechanism of action, excellent safety profile, and broad-spectrum activity against Candida and Aspergillus species.

Overview and Classification

  • Drug Class: Echinocandin antifungal

  • Brand Name: Cancidas

  • IUPAC Name: 1-[4-[(2-aminoethyl)amino]-N2-[(2R,3R,4R,5R)-5-[[(2R)-2-hydroxy-4-[[(2R)-2-hydroxy-3-phenylpropanoyl]amino]butanamido]-3,4-dihydroxycyclohexyl]-2-[(2S)-2-hydroxy-3-(4-hydroxyphenyl)propanamido]pentanediamide

  • Molecular Formula: C52H88N10O15

  • Molecular Weight: 1093.3 g/mol

Caspofungin is derived from a natural fermentation product of Glarea lozoyensis and is modified to improve pharmacokinetic properties.

Mechanism of Action

Caspofungin functions by inhibiting β-(1,3)-D-glucan synthase, an enzyme essential for the synthesis of glucan, a critical component of the fungal cell wall. This leads to:

  • Cell wall instability

  • Osmotic lysis

  • Cell death

Human cells lack β-(1,3)-D-glucan, making Caspofungin highly selective with a low toxicity profile. This cell wall-targeted mechanism also reduces the likelihood of cross-resistance with other antifungal classes like azoles or amphotericin B.

Spectrum of Activity

Caspofungin is fungicidal against most Candida species and fungistatic against Aspergillus spp. It is not effective against Cryptococcus neoformans, Fusarium spp., or Zygomycetes.

Effective Against:

  • Candida albicans

  • Candida glabrata

  • Candida tropicalis

  • Candida krusei

  • Aspergillus fumigatus

  • Aspergillus flavus

  • Aspergillus niger

Limited or No Activity Against:

  • Cryptococcus neoformans

  • Fusarium spp.

  • Mucorales (Zygomycetes)

Clinical Indications

Caspofungin is FDA-approved for the following indications:

1. Invasive Candidiasis

  • Candidemia and deep-seated Candida infections (intra-abdominal, peritonitis, pleural space)

  • Particularly useful in patients with neutropenia or those critically ill

2. Esophageal Candidiasis

  • Second-line option after fluconazole

  • Highly effective with low relapse rates

3. Empirical Therapy for Suspected Fungal Infections in Febrile Neutropenia

  • Used when patients with prolonged neutropenia and fever do not respond to broad-spectrum antibiotics

4. Invasive Aspergillosis (Salvage Therapy)

  • For patients who fail or cannot tolerate amphotericin B or voriconazole

  • Often used in combination with other antifungals for synergy

Off-label and investigational uses:

  • Prophylaxis in bone marrow and organ transplant recipients

  • Combination therapy in multidrug-resistant fungal infections

Pharmacokinetics

Property Details
Administration Intravenous only
Bioavailability Not applicable (IV only)
Protein Binding ~97%
Volume of Distribution ~9–10 L
Half-life 9–11 hours
Metabolism Slowly hydrolyzed and N-acetylated
Excretion Feces (41%), urine (35%)

Caspofungin is not significantly metabolized by the cytochrome P450 system, making it favorable for use in patients on multiple medications.

Dosage and Administration

Standard Dosing:

  • Loading dose: 70 mg IV on day 1

  • Maintenance dose: 50 mg IV daily

Hepatic Impairment:

  • Reduce maintenance dose to 35 mg daily in moderate hepatic impairment (Child-Pugh B)

Pediatric Use:

  • Dosed by body surface area: 50 mg/m²/day (maximum 70 mg)

Caspofungin is administered once daily via IV infusion over 1 hour.

Adverse Effects

Caspofungin is generally well tolerated. Common and uncommon adverse effects include:

System Adverse Effects
Hematologic Anemia, neutropenia, thrombocytopenia (rare)
Hepatic Elevated liver enzymes (AST, ALT, ALP, bilirubin)
Gastrointestinal Nausea, vomiting, diarrhea
Renal Rare nephrotoxicity
Dermatologic Rash, pruritus
Infusion-related Fever, phlebitis, histamine-mediated reactions

Infusion reactions (e.g., rash, facial swelling, bronchospasm) are rare but may be mitigated by slowing infusion rate or using antihistamines.

Drug Interactions

Caspofungin has minimal drug-drug interactions due to its limited involvement with cytochrome P450 enzymes. However:

  • Cyclosporine: May increase liver enzyme levels

  • Rifampin, carbamazepine, phenytoin: May reduce caspofungin levels by inducing metabolism

  • Tacrolimus: Slight increase in tacrolimus levels—monitor therapeutic drug levels

Resistance Mechanisms

Although still rare, resistance to caspofungin is an emerging concern, especially in Candida glabrata and Candida auris.

Mechanisms:

  1. FKS gene mutations: Alteration of glucan synthase enzyme, reducing caspofungin binding.

  2. Biofilm formation: Decreased drug penetration in biofilms leads to therapeutic failure.

Routine susceptibility testing is recommended in high-risk settings to monitor emerging resistance.

Comparison with Other Echinocandins

Feature Caspofungin Micafungin Anidulafungin
FDA approval date 2001 2005 2006
Half-life (hours) 9–11 10–17 24
Metabolism Peptide hydrolysis Hepatic Non-hepatic (chemical degradation)
Dosage Once daily IV Once daily IV Once daily IV
Pediatric use Approved Approved Approved

Caspofungin was the first echinocandin, and while newer agents like anidulafungin offer longer half-lives, all share similar efficacy and spectrum of activity.

Advantages of Caspofungin

  • Broad-spectrum antifungal activity

  • Minimal nephrotoxicity (ideal for renal-impaired patients)

  • Once-daily dosing

  • Few drug interactions

  • Safe in hepatic and critically ill patients (with dose adjustments)

  • Preferred in azole-resistant Candida and amphotericin-intolerant patients

Limitations

  • No oral formulation—limits outpatient use

  • Inactive against Cryptococcus and molds like Mucorales

  • Resistance is rare but increasing

  • Higher cost compared to fluconazole or amphotericin B

Clinical Trials and Guidelines

  • RESEARCH STUDIES: Numerous trials have shown caspofungin to be non-inferior or superior to fluconazole and amphotericin B in treating invasive candidiasis.

  • IDSA Guidelines: Recommends echinocandins (including caspofungin) as first-line therapy for candidemia in non-neutropenic adults.

It is also included in treatment guidelines for neutropenic fever, solid organ transplant recipients, and ICU patients with suspected fungal infections.

Future Directions and Research

Ongoing research is exploring:

  • Combination therapy: Caspofungin with azoles or amphotericin B for invasive mold infections.

  • Use in viral-fungal coinfections (e.g., COVID-19–associated pulmonary aspergillosis)

  • Development of oral echinocandins based on caspofungin structure

  • Extended-spectrum derivatives targeting resistant species like Candida auris

Conclusion

Caspofungin represents a major advancement in antifungal pharmacotherapy. With its novel mechanism of action, excellent safety profile, and broad efficacy against invasive candidiasis and aspergillosis, it plays a pivotal role in treating life-threatening mycoses, particularly in vulnerable patient populations.

While it has certain limitations, especially in terms of oral availability and spectrum gaps, caspofungin remains a go-to agent for clinicians managing systemic fungal infections in the ICU, oncology, and transplant settings. As resistance to older antifungal agents rises and immunosuppressed populations grow, caspofungin and its echinocandin class will likely remain at the forefront of antifungal strategy for years to come.